Pfizer PFE announced that the European Commission (EC) has granted approval to its JAK inhibitor drug, Xeljanz for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular ...
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs. The Food and Drug Administration (FDA) has ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that it will not meet the Prescription Drug User Fee Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results